Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
5.94
0.00 (0.00%)
May 14, 2025, 4:00 PM EDT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
8.18
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
10.56B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| Silence Therapeutics | 27.70M |
Innovent Biologics News
- 8 days ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study ... - GuruFocus
- 8 days ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema - PRNewsWire
- 9 days ago - Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 - PRNewsWire
- 15 days ago - Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies - PRNewsWire
- 17 days ago - Innovent Biologics Inc (IVBIY) Showcases Groundbreaking Preclinical Data at AACR 2025 | IVBIY ... - GuruFocus
- 17 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific ... - GuruFocus
- 17 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs - PRNewsWire
- 19 days ago - Innovent Biologics Inc (IVBIY) Secures NMPA Approval for Limertinib as First-Line Treatment for ... - GuruFocus